Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

(marketscreener.com) Data confirms the ability of the VeriStrat® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimenshttps://www.marketscreener.com/quote/stock/BIODESIX-INC-114282624/news/Biodesix-Presents-New-Data-from-the-INSIGHT-Study-at-the-2022-Society-for-Immunotherapy-of-Cancer-S-42271777/?utm_medium=RSS&utm_content=20221110